Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

BACKGROUND: Multiple early reports of patients admitted to hospital with COVID-19 showed that patients with chronic respiratory disease were significantly under-represented in these cohorts. We hypothesised that the widespread use of inhaled glucocorticoids among these patients was responsible for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramakrishnan, Sanjay, Nicolau, Dan V, Langford, Beverly, Mahdi, Mahdi, Jeffers, Helen, Mwasuku, Christine, Krassowska, Karolina, Fox, Robin, Binnian, Ian, Glover, Victoria, Bright, Stephen, Butler, Christopher, Cane, Jennifer L, Halner, Andreas, Matthews, Philippa C, Donnelly, Louise E, Simpson, Jodie L, Baker, Jonathan R, Fadai, Nabil T, Peterson, Stefan, Bengtsson, Thomas, Barnes, Peter J, Russell, Richard E K, Bafadhel, Mona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040526/
https://www.ncbi.nlm.nih.gov/pubmed/33844996
http://dx.doi.org/10.1016/S2213-2600(21)00160-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040526/
https://www.ncbi.nlm.nih.gov/pubmed/33844996
http://dx.doi.org/10.1016/S2213-2600(21)00160-0

Ejemplares similares